Praxis Precision Medicines Inc. (PRAX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRAX Stock Price Chart Interactive Chart >
PRAX Price/Volume Stats
|Current price||$8.41||52-week high||$23.56|
|Prev. close||$8.38||52-week low||$7.25|
|Day high||$8.50||Avg. volume||270,241|
|50-day MA||$9.63||Dividend yield||N/A|
|200-day MA||$15.62||Market Cap||382.76M|
Praxis Precision Medicines Inc. (PRAX) Company Bio
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.
Most Popular Stories View All
PRAX Latest News Stream
|Loading, please wait...|
PRAX Latest Social Stream
View Full PRAX Social Stream
Latest PRAX News From Around the Web
Below are the latest news stories about Praxis Precision Medicines Inc that investors may wish to consider to help them evaluate PRAX as an investment opportunity.
Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562
PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the first half of 2022 to explore the potential for PRAX-562 to treat rare DEEs BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system
A number of insiders bought Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock last year, which is great news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) gapped down before the market opened on Wednesday . The stock had previously closed at $19.01, but opened at $18.45. Praxis Precision Medicines shares last traded at $18.71, with a volume of 339 shares traded. Several research firms have weighed in on PRAX. Wedbush lowered their price target on shares 
HC Wainwright initiated coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX) in a report published on Thursday, PriceTargets.com reports. The firm issued a buy rating and a $48.00 target price on the stock. PRAX has been the topic of several other reports. Bank of America started coverage on shares of Praxis Precision Medicines in a 
Wall Street analysts expect Praxis Precision Medicines, Inc. (NASDAQ:PRAX) to post earnings of ($1.08) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Praxis Precision Medicines earnings. The highest EPS estimate is ($0.93) and the lowest is ($1.19). Praxis Precision Medicines posted earnings per share of ($0.87) 
PRAX Price Returns